Humanin

What it is

Humanin is a 24-amino-acid peptide first reported from the mitochondrial MT-RNR2 region. FDA registers it under UNII H975EUX36G. HNG, or S14G-Humanin, is a different synthetic analog—not a second name for native Humanin.

The human evidence in this draft measures endogenous circulating or tissue Humanin. It does not establish the identity, formulation, route, pharmacology, purity, sterility, stability, or clinical equivalence of an administered product. A GSRS record identifies a substance but does not establish approval.

Why people care

Humanin is discussed in longevity, metabolism, neuroprotection, and exercise contexts because cell and animal studies report stress-protective effects and human studies report associations with age or metabolic state. Those evidence types are often blurred into claims about an administered product even though the identified human record does not establish such a treatment effect.

What humans actually show

Humanin is a 24-amino-acid mitochondrial-derived peptide. The identified human literature measures endogenous Humanin as a biomarker or physiology signal rather than administering it as a treatment. The dated official searches did not identify an FDA-approved Humanin product or a human administration trial, so cell, animal, and biomarker findings cannot support treatment claims.

• biomarker — Fifty-five men with impaired glucose regulation randomized to resistance training, Nordic walking, or control for 12 weeks; Route: No Humanin was administered; skeletal-muscle Humanin protein was measured; Outcome: Change in muscle Humanin protein after exercise interventions: The paper reported a 35% increase in muscle Humanin protein after resistance training. The seam: Humanin was a measured tissue biomarker, not the randomized intervention; The result does not establish benefit from administering Humanin; The study does not define a therapeutic target concentration; Exercise effects cannot authenticate or predict a Humanin product.
• biomarker — Ten healthy untrained men in an acute high-intensity interval exercise experiment; Route: No Humanin was administered; muscle and plasma Humanin were measured; Outcome: Acute muscle and plasma Humanin responses to exercise: The study reported changes in muscle and plasma Humanin after the exercise session. The seam: Ten participants; Acute physiology rather than a patient-important outcome; No administered Humanin intervention; No chronic safety or efficacy inference.
• biomarker — Two hundred twenty-five adults across normal glucose tolerance, prediabetes, and type 2 diabetes groups; Route: No Humanin was administered; circulating Humanin was measured; Outcome: Between-group Humanin concentrations and metabolic correlations: The study reported lower circulating Humanin in the type 2 diabetes group and associations with metabolic measures. The seam: Cross-sectional design cannot establish direction or causality; Association does not establish treatment benefit; Assay and population differences limit transfer; The study does not define a target concentration.
• biomarker — Observational cardiac-operation and acute-kidney-injury registry populations; Route: No Humanin administration listed; tissue or plasma Humanin measurement; Outcome: Association of measured Humanin with perioperative or kidney-injury variables: The registries describe Humanin as a measured biomarker rather than a therapeutic intervention. The seam: Registry descriptions do not establish posted outcome results; Observational measurement cannot establish therapeutic efficacy; No administered product was identified; Registry status and results require rechecking at review.

Mechanistic and nonhuman evidence

• cell — Cultured neuronal and Alzheimer-disease-related cellular models; Route: Experimental Humanin exposure in vitro; Outcome: Cell survival under disease-related toxic stress: The original discovery papers reported cytoprotective effects in the studied cell systems. The seam: Cell survival is not a human clinical outcome; Experimental concentrations and models may not reflect human exposure; The studies do not establish product safety or efficacy; Mechanism does not establish approval.
• animal — Worm and mouse aging models within a mixed human and nonhuman study; Route: Genetic or experimental peptide interventions, including the HNG analogue; Outcome: Lifespan or healthspan-related measures: The paper reported lifespan or healthspan findings in nonhuman models alongside human circulating-Humanin associations. The seam: Nonhuman outcomes cannot establish a human treatment effect; HNG is not native Humanin; Mixed evidence types must not be collapsed; The study does not establish an approved product.
• animal — Male-rat model of paroxetine-associated reproductive and behavioral effects; Route: Experimental paroxetine and Humanin coadministration; Outcome: Reproductive, behavioral, hormonal, and neurochemical outcomes: The 2026 rat paper reported effects from the experimental combination. The seam: Rat evidence cannot establish human efficacy or compatibility; The model does not supply a clinical interaction conclusion; The study does not establish chronic human safety; Product identity and exposure do not transfer automatically.

FDA and U.S. status

An exact openFDA Drugs@FDA active-ingredient query for HUMANIN returned no match. The exact ClinicalTrials.gov intervention search returned three records, but review of their intervention fields found biomarker or rationale uses rather than Humanin administration. A focused PubMed clinical-trial screen likewise did not identify Humanin administration, and no FDA-approved Humanin prescribing information was identified. The database no-match is a dated search result and is not used alone.

Risks and warning limits

• not characterized: The identified human studies measured endogenous Humanin rather than administering it, so they do not characterize adverse effects of a Humanin product.
• not characterized: No FDA-approved Humanin prescribing information was identified in the dated official source set, so this draft assigns no FDA-labeled contraindications, warnings, or adverse-reaction frequencies.

What remains unknown

• Human pharmacokinetics, pharmacodynamics, and patient-important outcomes after administration of verified native Humanin remain unestablished by the identified evidence.
• Acute and chronic safety, immunogenicity, reproductive effects, contraindications, and interaction risks for administered Humanin remain inadequately characterized.
• The causal meaning of circulating or tissue Humanin measurements and any therapeutic target concentration remain unknown.
• Whether results with HNG or another analogue apply to native Humanin is not established.

Product identity and quality limits

• Native Humanin and HNG/S14G-Humanin are distinct exact substances; evidence must retain the tested identity.
• An endogenous Humanin assay result is not evidence about an administered product, and an FDA GSRS record is not an approval or formulation record.
• A Humanin name does not establish sequence, form, purity, concentration, sterility, aggregation state, stability, storage history, or biological activity.

What has been studied together

• Humanin with paroxetine — no direct evidence: A 2026 male-rat study evaluated whether Humanin modified paroxetine-associated reproductive, behavioral, and neuroendocrine findings. No direct human coadministration evidence or interaction conclusion was identified.
• Humanin with medicines, supplements, or other peptides — no direct evidence: The exact registry and focused clinical-publication screens did not identify an adequate human Humanin coadministration program. Missing evidence does not establish compatibility.

What people are hearing

These are claims this profile checks, not established conclusions.

• Claim under review: “Lower or higher measured Humanin proves that administering Humanin changes aging, diabetes, cognition, or recovery outcomes.”
• Claim under review: “Findings with the synthetic analogue HNG apply directly to native Humanin.”
• Claim under review: “A Humanin name or FDA substance record establishes an approved, trial-equivalent product.”

Questions readers raise

• No reproducible community sample was collected for this profile.

The community-signal layer is not efficacy or safety evidence. Its current limits are:

• No reproducible community sample has been collected for this profile.
• Self-reports would be subject to selection and reporting bias.
• The identity of a product described in a self-report could not be verified.
• Concurrent medicines, health conditions, diet, and behavior could confound an anecdote.
• Reported outcomes could not be independently verified.
• Anecdotes cannot establish efficacy, safety, approval, product identity, or interaction compatibility.

What would change this answer

• A registered, controlled human trial administering analytically verified native Humanin with posted or peer-reviewed outcomes would change the current biomarker-only human boundary for its exact intervention and population.
• An FDA approval action and final prescribing information would change the current unapproved status and establish product-specific indications, warnings, and identity.
• Direct human comparison of native Humanin with HNG could establish whether any analogue findings transfer; none was identified.

Sources and records

• WADA — 2026 Prohibited List

• Humanin substance record, UNII H975EUX36G — U.S. Food and Drug Administration Global Substance Registration System
• Drugs@FDA API exact active-ingredient search for Humanin — U.S. Food and Drug Administration
• ClinicalTrials.gov intervention search for Humanin — ClinicalTrials.gov
• PubMed Humanin clinical-trial publication search — National Library of Medicine
• Humanin in cardiac tissue and plasma around cardiac operation — ClinicalTrials.gov
• Plasma Humanin in acute kidney injury — ClinicalTrials.gov
• A rescue factor abolishing neuronal cell death by a wide spectrum of familial Alzheimer's disease genes and Abeta — PubMed
• Humanin, a novel neuroprotective factor, is a secreted peptide — PubMed
• Resistance exercise increases skeletal muscle Humanin protein in men with impaired glucose regulation — PubMed
• Acute high-intensity interval exercise and Humanin in human skeletal muscle and plasma — PubMed
• Circulating Humanin and glucose metabolism in adults — PubMed
• Humanin is a mitochondrial-derived peptide that is associated with healthspan and lifespan — PubMed
• Humanin peptide ameliorates reproductive dysfunction and restores neuroendocrine mechanisms in SSRI-treated male rats — PubMed